A Study to Test the Effectiveness and Safety of a New Medication in the Treatment of Schizophrenia

A Double-blind Fixed-dose Study of Lurasidone (SM-13496) and Placebo in the Treatment of Schizophrenia

A 6-week in-patient and out-patient study to test the effectiveness and safety of a new medication in the treatment of schizophrenia

Study will evaluate the efficacy of a new compound versus placebo in the treatment of patients with schizophrenia (diagnosed by DSM-IV criteria) as measured by reductions from baseline on the total score of the Brief Psychiatric Rating Scale (BPRS) as extracted from the Positive and Negative Syndrome Scale (PANSS).

Inclusion Criteria:

• Satisfy DSM-IV criteria for schizophrenia as established by SCID-CV
• The patient must agree to a voluntary hospitalization duration of 31 days minimum at the start of the treatment
• If female, must not be pregnant, or must be incapable of conceiving or be taking steps to prevent conception

Exclusion Criteria:

• The patient has used an investigational drug within the past 30 days
• The patient has participated in a previous study of this compound